ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

BBIO BridgeBio Pharma Inc

28.10
0.40 (1.44%)
取引時間後
最終更新日: 07:43:41
15分遅延
名称 銘柄コード 市場 種別
BridgeBio Pharma Inc BBIO NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.40 1.44% 28.10 07:43:41
始値 安値 高値 終値 前日終値
27.67 27.38 28.755 28.73 27.70
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0220:30GLOBEBridgeBio Pharma Reports First Quarter 2024 Financial..
2024/5/0220:00GLOBEBridgeBio launches BridgeBio Oncology Therapeutics (BBOT)..
2024/4/1020:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
2024/4/0802:15GLOBEBridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR)..
2024/3/2020:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
2024/3/0707:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/3/0707:13EDGAR2Form 8-K - Current report
2024/3/0613:53GLOBEBridgeBio Pharma Announces Pricing of Public Offering of..
2024/3/0507:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/3/0506:17GLOBEBridgeBio Pharma Announces Proposed Public Offering of..
2024/3/0421:00EDGAR2Form 8-K - Current report
2024/3/0416:30GLOBEBridgeBio Pharma and Bayer Announce European Licensing..
2024/2/2306:27EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/2221:31EDGAR2Form 8-K - Current report
2024/2/2221:30GLOBEBridgeBio Pharma Reports Fourth Quarter and Full Year 2023..
2024/2/2206:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2106:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1606:06EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1406:05EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
2024/2/1406:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0721:34GLOBEBridgeBio Pharma and Kyowa Kirin Announce Partnership with..
2024/2/0621:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
2024/2/0521:30GLOBEBridgeBio Pharma Announces U.S. Food and Drug Administration..
2024/2/0221:00GLOBEBridgeBio Pharma Shares Positive Results of Single-Arm Phase..
2024/1/3021:00PRNUSInvitae Partners with BridgeBio Pharma to Harness Genetic..
2024/1/1906:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1821:30EDGAR2Form 8-K - Current report
2024/1/1821:00GLOBEBridgeBio Pharma Secures up to $1.25 Billion of Capital from..
2024/1/1706:04EDGAR2Form 144 - Report of proposed sale of securities
2024/1/1107:15GLOBEBridgeBio Pharma Announces Publication of Positive Results..
2024/1/1021:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
2024/1/0907:14EDGAR2Form 8-K - Current report
2024/1/0606:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
2024/1/0406:30GLOBEBridgeBio Pharma to Participate in the J.P. Morgan..
2024/1/0321:30GLOBEBridgeBio announces FDA clearance of IND application for..
2023/12/2006:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1606:13EDGAR2Form 144 - Report of proposed sale of securities
2023/12/1321:30GLOBEBridgeBio Announces First Child Dosed in PROPEL 3, its Phase..
2023/12/0821:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
2023/12/0522:52DJNBridgeBio Seeks FDA Approval of Acoramidis in Transthyretin..
2023/12/0521:44GLOBEBridgeBio Pharma Announces Submission of New Drug..
2023/11/2106:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/1806:27EDGAR2Form 144 - Report of proposed sale of securities
2023/11/1806:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/1606:03EDGAR2Form 144 - Report of proposed sale of securities
2023/11/1300:30GLOBEBridgeBio Pharma Presents Additional Clinical Outcomes Data..
2023/11/0921:30GLOBEBridgeBio Pharma to Present Additional Data from the Phase 3..
2023/11/0821:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
2023/11/0305:59EDGAR2Form S-3ASR - Automatic shelf registration statement of..
2023/11/0220:31EDGAR2Form 8-K - Current report

最近閲覧した銘柄

Delayed Upgrade Clock